Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3460)
◆英語タイトル:Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3460
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company’s product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. It covers therapeutic areas such as blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus and pediatrics. Its products and services are used for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has its facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany.

Fresenius Kabi AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 13
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For US$37 Million 14
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 15
Partnerships 16
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 16
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 17
Licensing Agreements 18
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 18
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 19
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 20
Asset Transactions 21
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 21
Acquisition 22
NewCo Pharma Acquires CFL from Fresenius Kabi 22
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 23
Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 24
Fresenius Kabi (Singapore) To Delist Its Indian Arm 25
Linde To Acquire Calea France From Fresenius Kabi 26
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 27
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 29
Fresenius Kabi AG – Key Competitors 30
Fresenius Kabi AG – Key Employees 31
Fresenius Kabi AG – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 36
Recent Developments 37
Strategy And Business Planning 37
Jun 22, 2018: Fresenius Kabi UK expands operations in Runcorn, England 37
Nov 24, 2017: Fresenius Kabi opens production facility in Indonesia 38
Jul 06, 2017: Fresenius Kabi expands production site in Portugal 39
Financial Announcements 40
Feb 26, 2018: Fresenius remains on growth course after 14 straight record years 40
Nov 02, 2017: Fresenius reports another strong quarter and confirms guidance 47
Corporate Communications 49
Oct 10, 2017: Fresenius Kabi’s Generic Drugs Business Unit Head elected as president of Medicines for Europe 49
Legal and Regulatory 50
May 28, 2018: New EU Commission’s initiative “SPC manufacturing waiver” 50
Feb 26, 2018: Akorn Issues Statement on Investigation 51
Jan 29, 2018: HES solutions should remain on the market 52
Jan 03, 2018: USFDA issues warning letter to Fresenius Kabi for Baddi plant 53
Government and Public Interest 54
Nov 30, 2017: Statement by FDA Commissioner Scott Gottlieb, M.D., updating on Puerto Rico related medical product shortages 54
Other Significant Developments 55
Sep 08, 2017: Fresenius Kabi marks 20-year anniversary of Friedberg production site – Logistics center expansion planned 55
Mar 10, 2017: Fresenius Kabi builds new warehouse at Blonie production site 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 13
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For US$37 Million 14
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 15
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 16
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 17
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 18
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 19
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 20
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 21
NewCo Pharma Acquires CFL from Fresenius Kabi 22
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 23
Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 24
Fresenius Kabi (Singapore) To Delist Its Indian Arm 25
Linde To Acquire Calea France From Fresenius Kabi 26
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 27
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 29
Fresenius Kabi AG, Key Competitors 30
Fresenius Kabi AG, Key Employees 31
Fresenius Kabi AG, Other Locations 32
Fresenius Kabi AG, Subsidiaries 34
Fresenius Kabi AG, Joint Venture 36

List of Figures
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報(Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆